Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL Study: AVM0703 in Patients With Lymphoid Malignancies
NCT04329728Phase 2Recruiting
- Sponsor
- AVM Biotechnology
- Start
- Nov 2020
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AVM0703 in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), mantle cell lymphoma (MCL), primary mediastinal large B-cell lymphoma (PMBCL), Burkitt lymphoma (BL), sponsored by AVM Biotechnology. Started Nov 2020; status: recruiting.
02
Drugs
AVM0703
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)mantle cell lymphoma (MCL)primary mediastinal large B-cell lymphoma (PMBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT04329728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329728.